Form 4: HeartSciences Inc. Executive Andrew Simpson Reports Stock Option Grant

Andrew Simpson, Chairman, President, and CEO of HeartSciences Inc., reports the grant of employee stock options.

Summary

• Andrew Simpson, a director, officer (Chairman of the Board, President and Chief Executive Officer), of HeartSciences Inc. reported the grant of 45,000 employee stock options.
• The options were granted on January 16, 2025, with a strike price of $3.33.
• One-third of the options vest on January 16, 2026, with the remainder vesting in installments over the subsequent seven quarters, contingent on continued employment.
• The options also fully vest upon HeartSciences receiving regulatory clearance from the FDA for its MyoVista wavECG device or AI-ECG algorithm.
• The options expire on January 16, 2035.

Sentiment

Score: 7

Explanation: The document reports a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management with shareholder interests. The vesting conditions tied to regulatory approval add a layer of positive incentive.

Positives

• The vesting schedule incentivizes continued employment and achievement of regulatory milestones.
• The grant aligns executive interests with shareholder value creation.

Risks

• The vesting of a portion of the options is contingent on FDA regulatory clearance, which is not guaranteed.
• If regulatory clearance is not received, a portion of the options may not vest.

Future Outlook

The vesting of the options is tied to continued employment and regulatory milestones, suggesting a focus on long-term growth and regulatory success.

Industry Context

Stock option grants are a common form of executive compensation in the healthcare and technology industries, aligning management incentives with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in the technology and healthcare sectors.
• Companies like Medtronic and Boston Scientific also use stock options to incentivize their executives.
• The vesting schedule and performance-based conditions (such as regulatory approval) are also common practices to align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: Aligns executive incentives with company performance and shareholder value.
• Employees: Provides insight into executive compensation structure.
• Management: Incentivizes continued employment and achievement of regulatory milestones.

Key Dates

Keywords

stock options, HeartSciences, Andrew Simpson, executive compensation, Form 4, HSCS, vesting, regulatory clearance, MyoVista wavECG, AI-ECG algorithm